<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03895697</url>
  </required_header>
  <id_info>
    <org_study_id>ZP4207-17084</org_study_id>
    <nct_id>NCT03895697</nct_id>
  </id_info>
  <brief_title>A Trial to Compare the Efficacy and Safety of 2 Different Batches of Subcutaneous Dasiglucagon in Patients With T1DM</brief_title>
  <official_title>A Phase 3b, Randomized, Double-blind, Crossover Trial to Compare the Efficacy and Safety of 2 Different Batches of Subcutaneous Dasiglucagon in Patients With Type 1 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zealand Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zealand Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, double-blind, crossover trial to compare the efficacy and safety of 2 different
      batches of subcutaneous dasiglucagon in patients with type 1 diabetes mellitus
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 26, 2019</start_date>
  <completion_date type="Actual">July 29, 2019</completion_date>
  <primary_completion_date type="Actual">July 29, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to plasma glucose recovery</measure>
    <time_frame>0-45 minutes after dosing</time_frame>
    <description>Plasma glucose recovery is defined as first increase in plasma glucose of ≥20 mg/dL (1.1 mmol/L) from baseline during the hypoglycemic clamp procedure without administration of rescue intravenous glucose</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma glucose changes from baseline</measure>
    <time_frame>0-30 minutes after dosing</time_frame>
    <description>Plasma glucose changes from baseline at 30 minutes, at 20 minutes, at 15 minutes, and at 10 minutes after trial drug injection or at the time of rescue patient level).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics - Area under the effect curve 30 min</measure>
    <time_frame>0-30 minutes after dosing</time_frame>
    <description>Area under the baseline-adjusted effect curve (AUE) from zero up to the concentration at 30 minutes, AUE 0-30min</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics - Area under the effect curve 90 min</measure>
    <time_frame>0-90 minutes after dosing</time_frame>
    <description>Area under the baseline-adjusted effect curve (AUE) from zero up to the concentration at 90 minutes, AUE 0-90min</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics - Maximum plasma glucose concentration</measure>
    <time_frame>0-90 minutes after dosing</time_frame>
    <description>Change from baseline plasma glucose to maximum plasma glucose measure after dosing, CEmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics - Time maximum plasma glucose concentration</measure>
    <time_frame>0-90 minutes after dosing</time_frame>
    <description>Time to maximum change in plasma glucose measure from baseline, TEmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - Area under the plasma concentration-time curve 30 min</measure>
    <time_frame>0-30 minutes after dosing</time_frame>
    <description>Area under the concentration-time curve (AUC) from zero up to the concentration at 30 minutes, AUC0-30min</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - Area under the plasma concentration-time curve 300 min</measure>
    <time_frame>0-300 minutes after dosing</time_frame>
    <description>Area under the concentration-time curve (AUC) from zero up to the concentration at 300 minutes, AUC0-300min</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - Area under the plasma concentration curve Infinitely</measure>
    <time_frame>0-300 minutes after dosing</time_frame>
    <description>Area under the concentration-time curve from zero up to the concentration at infinitely after dosing, AUC0-inf</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - Maximum plasma concentration</measure>
    <time_frame>0-300 minutes after dosing</time_frame>
    <description>Measured maximum plasma drug concentration after dosing, Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - Time to maximum plasma concentration</measure>
    <time_frame>0-300 minutes after dosing</time_frame>
    <description>Sampling time until reaching Cmax, Tmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - Half-life</measure>
    <time_frame>0-300 minutes after dosing</time_frame>
    <description>Half-life dasiglucagon, t½</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - Volume of distribution</measure>
    <time_frame>0-300 minutes after dosing</time_frame>
    <description>Apparent volume of distribution of dasiglucagon, Vz/f</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - Mean residence time</measure>
    <time_frame>0-300 minutes after dosing</time_frame>
    <description>Mean residence time, MRT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics - Body clearance</measure>
    <time_frame>0-300 minutes after dosing</time_frame>
    <description>Total body clearance, CL/f</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety - Adverse events</measure>
    <time_frame>90 days</time_frame>
    <description>The incidence, type and severity of adverse events (AEs)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety - Number of rescue infusions</measure>
    <time_frame>0-90 minutes after dosing</time_frame>
    <description>Number of rescue infusions of IV glucose after trial drug administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety - Time to first rescue infusion</measure>
    <time_frame>0-90 minutes after dosing</time_frame>
    <description>Time to first rescue infusion of IV glucose after trial drug administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity - Occurrence of anti-drug antibodies</measure>
    <time_frame>60 days</time_frame>
    <description>Occurrence of antibodies against dasiglucagon</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">92</enrollment>
  <condition>Hypoglycemia</condition>
  <condition>Diabetes Mellitus, Type 1</condition>
  <arm_group>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>V2: Single fixed dose (sc injection) of dasiglucagon batch B then at V3: Single fixed dose (sc injection) of dasiglucagon batch A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>V2: Single fixed dose (sc injection) of dasiglucagon batch A then at V3: Single fixed dose (sc injection) of dasiglucagon batch B</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dasiglucagon</intervention_name>
    <description>Glucagon analogue</description>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_label>Sequence 2</arm_group_label>
    <other_name>ZP4207</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 1 diabetes mellitus for at least 1 year according to the diagnostic criteria as
             defined by the American Diabetes Association.

          -  Hemoglobin A1c &lt;10.0% at screening

          -  Treated with stable insulin treatment (defined as no more than a 10-unit daily
             variation in total daily insulin dose) 30 days prior to screening

        Exclusion Criteria:

          -  History of hypoglycemic events associated with seizures in the last year prior to
             screening

          -  History of severe hypoglycemia (an episode requiring assistance from another person)
             in the last month prior to screening

          -  Previous participation in a clinical trial within the dasiglucagon program
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stine J Maarbjerg</last_name>
    <role>Study Director</role>
    <affiliation>Zealand Pharma A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>LMC Diabetes &amp; Manna Research</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4G 3E8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>March 27, 2019</study_first_submitted>
  <study_first_submitted_qc>March 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 29, 2019</study_first_posted>
  <last_update_submitted>July 3, 2020</last_update_submitted>
  <last_update_submitted_qc>July 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>glucagon</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Hypoglycemia</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

